Sarepta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sarepta Therapeutics's estimated annual revenue is currently $645.6M per year.
- Sarepta Therapeutics received $375.0M in venture funding in November 2017.
- Sarepta Therapeutics's estimated revenue per employee is $387,259
- Sarepta Therapeutics's total funding is $1.4B.
- Sarepta Therapeutics's current valuation is $6.2B. (January 2022)
Employee Data
- Sarepta Therapeutics has 1667 Employees.
- Sarepta Therapeutics grew their employee count by 7% last year.
Sarepta Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | VP, General Manager EMEA Region | Reveal Email/Phone |
4 | VP, Head Gene Therapy & Gene Editing | Reveal Email/Phone |
5 | Head commercial traininb | Reveal Email/Phone |
6 | Head Global Medical Affairs Leads | Reveal Email/Phone |
7 | VP, Head Clinical Development | Reveal Email/Phone |
8 | VP, Commercial and Medical Affairs Operations | Reveal Email/Phone |
9 | EVP, Head R&D and Chief Scientific Officer | Reveal Email/Phone |
10 | SVP, Deputy General Counsel | Reveal Email/Phone |
Sarepta Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Sarepta Therapeutics?
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company's programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For more information, please visit www.sarepta.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.4B
Total Funding
1667
Number of Employees
$645.6M
Revenue (est)
7%
Employee Growth %
$6.2B
Valuation
N/A
Accelerator
Sarepta Therapeutics News
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics,...
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics,...
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for...
Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior yearIn light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million CAMBRIDGE, Mass., No ...
Sarepta is working hard to develop precision genetic medicines for patients with rare diseases who often have limited or no treatment options, including Duchenne. Clinical trials are critical for understanding the safety and effectiveness of our investigational medicines. The results of these st ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $420.6M | 1669 | 5% | N/A |
#2 | $643.4M | 1702 | 3% | N/A |
#3 | $267.8M | 1875 | -4% | N/A |
#4 | $376.5M | 1921 | N/A | N/A |
#5 | $487.9M | 1936 | -10% | N/A |
Sarepta Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-03-27 | $22.0M | Private Equity Fina | Article | |
| 2003-05-06 | $15.0M | Private Placement | Article | |
| 2003-12-05 | $15.0M | Equity Placement | Article | |
| 2005-10-04 | $109.0M | Undisclosed | Article | |
| 2005-11-15 | $22.6M | Undisclosed | Rodman and Renshaw LLC | Article |
| 2007-12-21 | $20.0M | Undisclosed | Article | |
| 2009-02-04 | $16.5M | Undisclosed | Eastbourne Capital Management | Article |
| 2009-08-21 | $30.0M | Undisclosed | Jefferies & Company Inc | Article |
| 2011-04-04 | $30.0M | Undisclosed | Lazard Capital Markets LLC, Piper Jaffray & Co | Article |
| 2014-04-25 | $94.5M | Undisclosed | Article | |
| 2015-06-30 | $40.0M | Undisclosed | Midcap Financial | Article |
| 2015-10-07 | $127.0M | Undisclosed | Credit Suisse | Article |
| 2016-06-10 | $37.5M | Undisclosed | Credit Suisse | Article |
| 2016-09-23 | $225.0M | Undisclosed | J.P. Morgan | Article |
| 2016-09-26 | $300.0M | Undisclosed | J.P. Morgan | Article |
| 2017-07-19 | $100.0M | Undisclosed | Article | |
| 2017-07-25 | $287.5M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2017-11-09 | $375.0M | Undisclosed | Article |